Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

• Published in: Diabetes care Vol. 33; no. 2; pp. 428 - 433
• Main Authors: Drucker, Daniel J, Sherman, Steven I, Gorelick, Fred S, Bergenstal, Richard M, Sherwin, Robert S, Buse, John B
• Format: Journal Article
• Language: English
• Published: Alexandria, VA American Diabetes Association 01.02.2010
• Subjects: Biological and medical sciences; Cancer; Care and treatment; Complications and side effects; Diabetes; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - epidemiology; Diabetes therapy; Diabetes. Impaired glucose tolerance; Drug Administration Schedule; Drug therapy; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Glucagon-Like Peptide 1 - agonists; Humans; Hyperglycemia; Hypoglycemic Agents - classification; Hypoglycemic Agents - therapeutic use; Incidence; Incretins - adverse effects; Incretins - therapeutic use; Medical research; Medical sciences; Metabolic diseases; Miscellaneous; Peptides - administration & dosage; Peptides - therapeutic use; Pharmaceutical industry; Prevalence; Public health. Hygiene; Public health. Hygiene-occupational medicine; Reviews/Commentaries/ADA Statements; Risk Assessment; Risk factors; Rodents; Treatment Outcome; Type 2 diabetes; Venoms - administration & dosage; Venoms - therapeutic use; United States; Switzerland; Endocrinopathy; Type 2 diabetes; Human; Evaluation; Incretin; Treatment; Nutrition; Efficiency; Risk factor; Metabolic diseases; Risk; Endocrinology
• ISSN: 0149-5992; 1935-5548
• DOI: 10.2337/dc09-1499

Limited evidence suggests that GLP-I may also preserve ventricular function and improve outcomes in human subjects with heart failure or myocardial infarction (11,12). [...] both exenatide and liraglutide reduce blood pressure, body weight, and plasma lipid profiles in subjects with type 2 diabetes (13), raising the hope that longterm treatment with these agents may reduce the incidence of cardiovascular events.\n However, two safety issues have been raised - pancreatitis and medullary carcinoma of the thyroid.